

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary ALK-Driven Neuroblastoma

Cancer Discovery

6, 96-107

DOI: [10.1158/2159-8290.cd-15-1056](https://doi.org/10.1158/2159-8290.cd-15-1056)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 75968-75980.	0.8	12
2	Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 762-767.	0.9	18
3	The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 941-52.	1.2	62
4	Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4948-4964.	2.9	277
5	Novel targeted therapy for treatment of relapsed and refractory neuroblastoma. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2016, 4, 162-169.	0.1	0
6	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16078.	18.1	907
7	Second- and third-generation ALK inhibitors for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 19.	6.9	116
8	Targeting ALK: The Ten Lives of a Tumor. <i>Cancer Discovery</i> , 2016, 6, 20-21.	7.7	5
9	ALK: a tyrosine kinase target for cancer therapy. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001115.	0.5	131
10	Molecular Genetics of Neuroblastoma. , 2017, , 83-125.		0
11	<i>ALK</i> gene alterations in cancer: biological aspects and therapeutic implications. <i>Pharmacogenomics</i> , 2017, 18, 277-292.	0.6	8
12	Advances in emerging drugs for the treatment of neuroblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 63-75.	1.0	36
13	Neuroblastoma treatment in the post-genomic era. <i>Journal of Biomedical Science</i> , 2017, 24, 14.	2.6	82
14	First macrocyclic 3 rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. <i>European Journal of Medicinal Chemistry</i> , 2017, 134, 348-356.	2.6	79
15	The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. <i>Cancer Letters</i> , 2017, 400, 61-68.	3.2	37
16	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> . 2017. 12. 1-11.	2.5	28
17	Emerging and investigational therapies for neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 355-368.	0.5	27
18	Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. <i>Blood</i> , 2017, 129, 823-831.	0.6	76

#	ARTICLE	IF	CITATIONS
19	Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 2856-2868.	3.2	76
20	<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti- <i>ALK</i> Targeted Therapy. <i>Oncologist</i> , 2017, 22, 1444-1450.	1.9	81
21	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	85
22	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. <i>Science Signaling</i> , 2017, 10, .	1.6	41
23	Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in <i>ALK</i> F1174L Drug-Resistant Neuroblastoma Preclinical Models. <i>Translational Oncology</i> , 2017, 10, 604-611.	1.7	12
24	Molecular mechanisms and therapeutic targets in neuroblastoma. <i>Pharmacological Research</i> , 2018, 131, 164-176.	3.1	53
25	Too many targets, not enough patients: rethinking neuroblastoma clinical trials. <i>Nature Reviews Cancer</i> , 2018, 18, 389-400.	12.8	67
26	Cell death-based treatment of neuroblastoma. <i>Cell Death and Disease</i> , 2018, 9, 113.	2.7	34
27	The <i>ALK</i> receptor in sympathetic neuron development and neuroblastoma. <i>Cell and Tissue Research</i> , 2018, 372, 325-337.	1.5	31
28	Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 250-257.	3.0	17
29	ALKs are in vivo ligands for <i>ALK</i> family receptor tyrosine kinases in the neural crest and derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E630-E638.	3.3	68
30	Activated <i>ALK</i> signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. <i>Oncogene</i> , 2018, 37, 1417-1429.	2.6	45
31	Neuroblastoma: clinical and biological approach to risk stratification and treatment. <i>Cell and Tissue Research</i> , 2018, 372, 195-209.	1.5	184
32	Precision medicine in pediatric oncology. <i>Molecular and Cellular Pediatrics</i> , 2018, 5, 6.	1.0	37
33	Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3448.	1.8	45
34	Entrectinib and other <i>ALK/TRK</i> inhibitors for the treatment of neuroblastoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3549-3561.	2.0	35
35	Integrated proximal proteomics reveals <i>IRS2</i> as a determinant of cell survival in <i>ALK</i> -driven neuroblastoma. <i>Science Signaling</i> , 2018, 11, .	1.6	33
36	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213

#	ARTICLE	IF	CITATIONS
37	Molecularly Targeted Therapy for Neuroblastoma. <i>Children</i> , 2018, 5, 142.	0.6	28
38	Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylamino-pyrimidine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 322-333.	2.6	16
39	Design, synthesis and biological evaluation N2-(2-alkoxy-6-aliphatic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 667 Td (aminopyridin-3-yl)-2, inhibitors. <i>Bioorganic Chemistry</i> , 2018, 81, 689-699.	2.0	5
40	ALK in Neuroblastoma: Biological and Therapeutic Implications. <i>Cancers</i> , 2018, 10, 113.	1.7	105
41	Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 13.	0.8	5
42	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002550.	0.5	47
43	Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111571.	2.6	13
44	Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy. <i>Cancer Cell</i> , 2019, 36, 345-347.	7.7	2
45	Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?. <i>Medical Science Monitor</i> , 2019, 25, 888-892.	0.5	34
46	Advanced Semiconductor Packaging Materials “Copper with Bamboo Structure.”, 2019, , .		0
47	An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115051.	1.4	8
48	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. <i>Oncotarget</i> , 2019, 10, 4937-4950.	0.8	5
49	Drug-resistance mechanisms of three mutations in anaplastic lymphoma kinase against two inhibitors based on MM/PBSA combined with interaction entropy. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 20951-20964.	1.3	9
50	Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. <i>Clinical Lung Cancer</i> , 2019, 20, 297-304.e1.	1.1	14
51	Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma. <i>Oncology Letters</i> , 2019, 17, 3323-3329.	0.8	4
52	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	44
53	Current management of neuroblastoma and future direction. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 38-43.	2.0	60
54	Neuroblastoma Pathology and Classification for Precision Prognosis and Therapy Stratification. , 2019, , 1-22.		3

#	ARTICLE	IF	CITATIONS
55	Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient. <i>Thoracic Cancer</i> , 2019, 10, 1252-1255.	0.8	6
56	Autophagy and Novel Therapeutic Strategies in Neuroblastoma. , 2019, , 95-112.		1
57	Novel Therapeutic Targets in Neuroblastoma. , 2019, , 231-261.		1
58	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. , 2019, , 263-281.		1
59	Targeting anaplastic lymphoma kinase in neuroblastoma. <i>Apmis</i> , 2019, 127, 288-302.	0.9	53
60	Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. <i>Scientific Reports</i> , 2019, 9, 2199.	1.6	14
61	Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors. <i>PLoS ONE</i> , 2019, 14, e0224227.	1.1	6
62	Neuroblastoma in Adolescents and Children Older than 10 Years: Unusual Clinicopathologic and Biologic Features. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 586-595.	0.3	4
63	Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring <i>ALK</i> Y1278S Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	5
64	Lorlatinib: First Global Approval. <i>Drugs</i> , 2019, 79, 93-98.	4.9	75
65	Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma. <i>Molecular Cancer Research</i> , 2019, 17, 676-685.	1.5	30
67	Design, synthesis and biological evaluation of 2-arylamino-pyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-11/2 ALK inhibitors. <i>Bioorganic Chemistry</i> , 2020, 94, 103456.	2.0	7
68	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. <i>Cancers</i> , 2020, 12, 2989.	1.7	16
69	1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-yl)ethanone (ZX-42), a novel ALK inhibitor, induces apoptosis and protective autophagy in H2228 cells. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1370-1382.	1.2	2
70	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	1.3	42
71	Mouse models of high-risk neuroblastoma. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 261-274.	2.7	17
72	Kinome multigenic panel identified novel druggable EPHB4 somatic variant in high-risk neuroblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6459-6471.	1.6	7
73	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157

#	ARTICLE	IF	CITATIONS
74	Landscape of drug-resistance mutations in kinase regulatory hotspots. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	15
75	Molecular targeting therapies for neuroblastoma: Progress and challenges. <i>Medicinal Research Reviews</i> , 2021, 41, 961-1021.	5.0	150
76	Resistance mechanisms to ALK TKIs in tumors other than lung cancer. , 2021, , 101-121.		0
77	Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma. , 2021, , 161-175.		0
78	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of <i>ALK</i> mutation. <i>EMBO Journal</i> , 2021, 40, e105784.	3.5	35
79	Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase I1170N-activating mutation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28916.	0.8	1
80	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). <i>Clinical Cancer Research</i> , 2021, 27, 3543-3548.	3.2	59
81	Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2019132118.	3.3	3
82	Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 654103.	1.8	5
83	Venetoclax-based Rational Combinations are Effective in Models of <i>MYCN</i> -amplified Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1400-1411.	1.9	10
84	Advances in pharmacotherapy for neuroblastoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2383-2404.	0.9	6
85	Downregulation of PDGFR β Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor. <i>Translational Oncology</i> , 2021, 14, 101099.	1.7	3
86	Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. <i>Cancers</i> , 2021, 13, 3531.	1.7	9
87	Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed <i>ALK</i> F1174L-mutated neuroblastoma. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006064.	0.5	16
88	An update of new small-molecule anticancer drugs approved from 2015 to 2020. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113473.	2.6	27
89	Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update. <i>Pharmaceutics</i> , 2021, 13, 1427.	2.0	10
90	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	1.3	34
91	Management of ALK positive patients with tumors other than lung cancer. , 2021, , 71-86.		0

#	ARTICLE	IF	CITATIONS
92	Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115719.	1.4	6
93	Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. <i>Oncotarget</i> , 2016, 7, 87301-87311.	0.8	20
94	TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. <i>Oncotarget</i> , 2016, 7, 23715-23729.	0.8	17
95	Targeting MYCN and ALK in resistant and relapsing neuroblastoma. , 2019, 2, 803-812.		5
96	A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Translational Cancer Research</i> , 2017, 6, S78-S82.	0.4	8
97	Molecular Sequence of Events and Signaling Pathways in Cerebral Metastases. <i>Anticancer Research</i> , 2018, 38, 1859-1877.	0.5	6
98	ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor. <i>Cancer Research and Treatment</i> , 2018, 50, 495-505.	1.3	12
99	Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models. <i>ELife</i> , 2017, 6, .	2.8	35
101	ALK and neuroblastoma: from molecular genetics to clinics. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2019, 6, 54-60.	0.1	1
102	High-Risk Neuroblastoma and Current Protocols. , 2020, , 213-235.		1
103	Biology of Neuroblastoma. , 2020, , 17-28.		0
104	Prognostic Factors and Risk Stratification. , 2020, , 271-292.		0
105	Evolving treatments in high-risk neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 497-506.	0.5	2
106	MiR-300 suppresses laryngeal squamous cell carcinoma proliferation and metastasis by targeting ROS1. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 3903-3911.	0.0	11
108	Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12883.	1.8	9
109	Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. <i>Molecules</i> , 2021, 26, 7069.	1.7	4
110	ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. <i>Nature Communications</i> , 2021, 12, 6813.	5.8	21
111	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	5.1	37

#	ARTICLE	IF	CITATIONS
112	Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors. <i>Cancer Research</i> , 2022, 82, 484-496.	0.4	18
113	Anaplastic lymphoma kinase inhibitors and their effect on the kidney. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1475-1482.	1.4	5
114	GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. <i>Npj Precision Oncology</i> , 2022, 6, 16.	2.3	5
115	Recent advances in the developmental origin of neuroblastoma: an overview. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 92.	3.5	46
116	Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies. <i>Current Oncology Reports</i> , 2022, 24, 1053-1062.	1.8	27
117	Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 336-346.	1.9	20
118	Novel TENM3â€“ALK fusion is an alternate mechanism for ALK activation in neuroblastoma. <i>Oncogene</i> , 2022, 41, 2789-2797.	2.6	3
119	Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations. <i>Cancer Research Communications</i> , 2022, 2, 277-285.	0.7	4
121	Advancing therapy for neuroblastoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 515-533.	12.5	97
122	Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. <i>Cancer Discovery</i> , 2022, 12, 2800-2819.	7.7	16
123	Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. <i>Translational Lung Cancer Research</i> , 2022, 11, 2164-2166.	1.3	1
125	Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. <i>Clinical Cancer Research</i> , 2023, 29, 1317-1331.	3.2	11
126	Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma. <i>Current Pharmacology Reports</i> , 0, , .	1.5	0
127	Patient-derived models: Advanced tools for precision medicine in neuroblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
128	Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. <i>Nature Medicine</i> , 2023, 29, 1092-1102.	15.2	26
129	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664.	2.0	2
130	Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
131	Genomics-Driven Precision Medicine in Pediatric Solid Tumors. <i>Cancers</i> , 2023, 15, 1418.	1.7	0

#	ARTICLE	IF	CITATIONS
143	Update in Solid Tumors of Childhood. , 2023, , 629-662.		0
144	Stem Cell Therapy for High-Risk Neuroblastoma: Stem Cell Transplantation and Targeting Cancer Stem Cells. , 2024, , .		0